Business, energy, technology, markets and global industry news from Business News Today

AstraZeneca

PharmaDeviceNews AstraZeneca
A representative image of advanced single-cell analysis and AI-driven drug discovery workflows, reflecting Illumina’s Billion Cell Atlas initiative with AstraZeneca, Merck, and Eli Lilly to accelerate next-generation precision medicine.
Medical Devices & Diagnostics

Illumina’s Billion Cell Atlas marks inflection point for AI-enabled drug discovery in 2026

Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks

Read More
Representative image illustrating FDA Breakthrough Therapy designation. Enhertu’s latest nod in HER2-positive early breast cancer could signal a major shift in post-neoadjuvant treatment strategy.
Pharma & Biotech

AstraZeneca, Daiichi Sankyo push Enhertu into early breast cancer with new FDA nod

AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results

Read More
Representative image of PARP inhibitor research and formulation. Relevant to our feature on how drugs like Rubraca, Lynparza, and others are reshaping prostate cancer treatment after setbacks in ovarian cancer.
Features & Analysis

Beyond ovarian and breast cancer: Are PARP inhibitors finally proving their worth in urologic oncology?

The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life. The December 2025

Read More
Pharma & Biotech

AstraZeneca secures global rights to Jacobio Pharma’s Pan‑KRAS JAB‑23E73 in high‑stakes KRAS market expansion

Find out how Jacobio Pharma’s global licensing deal with AstraZeneca could reshape KRAS‑targeted cancer therapy development.

Read More
Pharma & Biotech

Enhertu plus pertuzumab receives FDA approval for 1st-line HER2-positive metastatic breast cancer: Is the new standard of care here?

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, has received U.S. Food and Drug Administration approval as a first-line treatment for patients with unresectable or metastatic HER2-positive breast cancer, based on results from the DESTINY-Breast09 Phase III trial. The approval marks the first new frontline treatment in over a decade

Read More
AstraZeneca’s Saphnelo pen approved in EU as biologic lupus treatment advances
Pharma & Biotech

AstraZeneca gains EU approval for Saphnelo self-injection pen in lupus treatment

AstraZeneca has received European Commission approval for a new subcutaneous formulation of Saphnelo (anifrolumab), allowing adult patients with systemic lupus erythematosus (SLE) to self-administer the drug via a once-weekly pre-filled pen. The regulatory decision follows a positive opinion from the Committee for Medicinal Products for Human Use and is supported by data from the Phase

Read More
Medical Devices & Diagnostics

What Pillar Biosciences’ China move means for decentralized oncology diagnostics

Pillar Biosciences has expanded its collaboration with AstraZeneca to bring its next-generation sequencing-based liquid biopsy kits to China, aiming to accelerate localized tumor profiling and broaden access to precision oncology diagnostics. The partnership, which includes Shanghai Zhengu Biological Technology Co., Ltd., is designed to support assay implementation across Chinese hospital laboratories to reduce diagnostic turnaround

Read More